What is investment? �
I would argue there are three definitions of investment, which vary depending on the discipline being discussed. There is a general definition of investment followed by more specific ones if you are looking at investment from the perspectives of finance or economics.�
My definition of investment is: the transfer to others of some asset now with the rational expectation of receiving a return in the future.
I include a wider range of assets in my thinking than just money. For both the investment and the return, any asset qualifies: money, time, health, reputation, relationships, IQ, EQ, mastery.
Many people underinvest or neglect various assets of their life (health, relationships) while focusing on others such as their financial assets or immediate happiness to the detriment of their life long-term. With all investing, you need to be careful about being too focused on short-term gains and consider the long term.
Warren Buffett, chairman and CEO of Berkshire Hathaway and one of the world's greatest investors, has spoken greatly about the various assets of life and lessons he's learned. For more on this, you can read about some of the smartest things Warren Buffet has said here.
Hot Computer Hardware Companies To Invest In Right Now: Luminex Corporation(LMNX)
Luminex Corporation engages in the development, manufacture, and sale of proprietary biological testing technologies and products for the life sciences and diagnostic industries. It offers xMAP technology, an open architecture and multiplexing technology that allows simultaneous analysis of approximately 500 bioassays from a drop of fluid by reading biological tests on the surface of microscopic polystyrene beads called microspheres. The company?s xMAP technology is used in various segments of the life sciences industry, such as the fields of drug discovery and development, clinical diagnostics, genetic analysis, bio-defense, food safety, and biomedical research. It operates in two segments, Technology and Strategic Partnerships; and Assays and Related Products. The Technology and Strategic Partnerships segment provides Luminex LX 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; and MAGP IX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids. This segment also offers consumables comprising dyed polystyrene microspheres and sheath fluids. The Assays and Related Products segment develops and sells assays on xMAP technology for use on its installed base of systems. This segment?s products are focused on the human genetics, personalized medicine, and infectious disease segments of the genetic testing market. This segment provides various assay products, which consist of a combination of chemical and biological reagents, and company?s proprietary bead technology used to perform diagnostic and research assays on samples. It serves pharmaceutical companies, clinical laboratories, research institutions, and medical institutions in the United States, Europe, Asia, Canada, and Australia. The company was founded in 1995 and is headquartered in Austin, Texas.
Advisors' Opinion:- [By Markus Aarnio]
Illumina's competitors include Affymetrix (AFFX), Life Technologies Corporation (LIFE) and Luminex Corporation (LMNX). Here is a table comparing these companies.
- [By Seth Jayson]
There's no foolproof way to know the future for Luminex (Nasdaq: LMNX ) or any other company. However, certain clues may help you see potential stumbles before they happen -- and before your stock craters as a result.
- [By Seth Jayson]
Basic guidelines
In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at Luminex (Nasdaq: LMNX ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is Luminex doing by this quick checkup? At first glance, not so great. Trailing-12-month revenue increased 9.1%, and inventory increased 32.2%. Comparing the latest quarter to the prior-year quarter, the story looks potentially problematic. Revenue grew 9.2%, and inventory grew 32.2%. Over the sequential quarterly period, the trend looks worrisome. Revenue dropped 4.2%, and inventory grew 8.0%. - [By Roberto Pedone]
A health care stock that insiders are jumping into here is Luminex (LMNX), which develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. Insiders are buying this stock into notable strength, since shares are up 23.2% so far in 2013.
Luminex has a market cap of $859 million and an enterprise value of $784 million. This stock trades at a premium valuation, with a price-to-sales of 119.83 and a price-to-book of 33.63. Its estimated growth rate for this year is 36.7%, and for next year it's pegged at 51.2%. This is a cash-rich company, since the total cash position on its balance sheet is $42.97 million and its total debt is just $1.67 million.
A director just bought 27,000 shares, or about $540,000 worth of stock, at $20.01 per share.
From a technical perspective, LMNX is currently trending above its 200-day and just below is 50-day moving average, which is neutral trendwise. This stock recently gapped down sharply from $23.50 to $19.75 a share with heavy downside volume flows. Following that move, shares of LMNX have started to rebound off $19.75 and the stock is starting to push within range of triggering a near-term breakout trade.
If you're bullish on LMNX, then look for long-biased trades as long as this stock is trending some key near-term support at $19.75, and then once it breaks out above its 50-day at $21.14 a share and above its gap down day high of $21.83 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 206,755 shares. If that breakout hits soon, then LMNX will set up to re-test or possibly take out its 52-week high at $24.10. Any high-volume move above that level will then give LMNX a chance to tag $25 to $26.
5 Best Long Term Stocks To Buy For 2014: Acorda Therapeutics Inc.(ACOR)
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its marketed products include Ampyra (dalfampridine), a potassium channel blocker for improving walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS with walking disability under the Fampyra name internationally. Its lead research and development programs include three biologic therapeutic approaches for restoring neurologic and cardiac function, which comprise Neuregulin Program for developing Glial Growth Factor 2, a molecule in the Phase I clinical trial for the treatment of heart failure; Remyelina ting Antibodies Program for developing rHIgM22, an antibody in the preclinical stage for treating MS; and Chondroitinase Program, a research stage program focused on developing chontroitinase as a therapeutic to break down inhibitory factors in the scar tissue that develops as a result of an injury to the CNS. In addition, the company has in-licensed a clinical-stage program, AC105, to develop an acute treatment for neurological trauma. It has collaboration agreement with Biogen Idec International GmbH to develop and commercialize products containing aminopyridines to the treatment of MS. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Hawthorne, New York.
Advisors' Opinion:- [By Anna Prior]
Acorda Therapeutics Inc.(ACOR) said Monday that its Phase 3 study of its dalfampridine-QD treatment in people with post-stroke walking deficits will start later than originally expected. Shares of the biotechnology company fell 3.4% to $34 in premarket trading.
- [By Jonas Elmerraji]
Nearest Resistance: $40��br>Nearest Support: $29��br>Catalyst: Civitas Acquisition
Small-cap biopharma firm Acorda Therapeutics (ACOR) made the most-actives list on Wednesday after the firm blasted 28% higher during the session on acquisition news. No, it wasn't Acorda that was getting acquired. Instead, ACOR announced that it was purchasing Civitas Therapeutics, the developer of an experimental Parkinson's disease treatment.
The news broke ACOR out of a downtrend that had harangued shares since the first quarter, but that doesn't mean you should jump into this name just yet. Shares are within grabbing distance of an important resistance level at $40, a level that's swatted down ACOR's buying pressure in the past. At this point, it makes sense to wait to see if this name can catch a bid above $40 before buying here.
Must Read: Warren Buffett's Top 10 Dividend Stocks
- [By Garrett Cook]
Acorda Therapeutics (NASDAQ: ACOR) was down, falling 7.14 percent to $32.76 after the company announced a public offering of $300 million principal amount of convertible senior notes due 2021.
5 Best Long Term Stocks To Buy For 2014: Bouygues SA (BOUYF.PK)
Bouygues SA is a France-based group that operates in two sectors: Telecommunications and Media, and Construction. The Construction division comprises three core subsidiaries: Bouygues Construction, specializing in building and public works activities, notably in the areas of electrical engineering, and facility maintenance; Bouygues Immobilier, a property development company, whose activities include the development of residential, corporate and commercial properties, and the execution of urban development schemes, and Colas, engaged in the construction and maintenance of transport, urban development and leisure infrastructure. The Telecommunications and Media division of the Group comprises two companies: TF1, specializing in audiovisual and cinema production, the acquisition and sale of audiovisual rights, and the publishing and distribution of compact discs, among others, and Bouygues Telecom, which offers mobile telephone and broadband Internet services. Advisors' Opinion:- [By Mike Arnold]
I normally don't look at charts much, but comparing Orange to its competitors in the French telecommunications market is quite fascinating. As one can see, incumbents Bouygues (BOUYF.PK) and Vivendi (VIVHY.PK) (owner of SFR) saw similar price declines. The market, on the other hand, rapidly bid up the price of new entrant Iliad SA (ILIAF.PK), as a result of forecasts for Iliad to capture significant mobile market share (which it did, around 10%). The wide divergence in price relative to changes in underlying value favor going long the incumbents, including Orange. Because this time it's different.
5 Best Long Term Stocks To Buy For 2014: Time Warner Cable Inc(TWC)
Time Warner Cable Inc., together with its subsidiaries, operates as a cable operator in the United States. It offers video, high-speed data, and voice services over its broadband cable systems to residential and commercial customers. The company provides a range of video services, including on-demand, high-definition (HD), and digital video recorder (DVR) services; residential high-speed data services with connection to the Internet; wireless mobile broadband Internet services; and digital phone services to residential customers. It offers video programming tiers and music services; high-speed data, networking, and transport services; and commercial digital phone service to small and medium-sized businesses under the Time Warner Cable Business Class brand. Further, Time Warner Cable Inc. sells advertising to various national, regional, and local customers. As of June 30, 2011, the company served approximately 14.5 million residential and commercial customers in the New Yor k State, the Carolinas, Ohio, southern California, and Texas. Time Warner Cable Inc. is based in New York, New York.
Advisors' Opinion:- [By WALLSTCHEATSHEET]
Time Warner Cable provides entertainment, voice, and high-speed data services to a growing customer base in the United States. The company�� battle with CBS has ended to Time Warner Cable’s disadvantage. The stock has been trending higher in recent years and is now pulling-back from all-time high prices. Over the last four quarters, earnings and revenues have been rising, however, investors have expected a little more from the company. Relative to its peers and sector, Time Warner Cable has been a weak year-to-date performer. WAIT AND SEE if Time Warner Cable can stabilize at current prices.
- [By Brian Stelter]
Consolidation among content producers has been widely expected in recent months because of two big deals on the other side, the distribution side: Comcast's pending merger with Time Warner Cable (TWC) and AT&T's pending acquisition of DirecTV (DTV).
No comments:
Post a Comment